financetom
Business
financetom
/
Business
/
US banks face loss risk from multi-family property loan exposure, says Fitch
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US banks face loss risk from multi-family property loan exposure, says Fitch
Mar 28, 2024 1:30 AM

WASHINGTON (Reuters) - U.S. banks with significant lending exposure to some multi-family properties and particularly rent-controlled housing are vulnerable to posting losses this year on rising costs facing landlords, according to Fitch Ratings analysts.

On a Wednesday call, Fitch Ratings analysts highlighted the risks facing banks which have underwritten loans behind apartment complexes and other multifamily properties.

Lending by banks to multifamily borrowers grew 32% since 2020 to $613 billion at the end of 2023, according to a March 19 report by Fitch.

But supply has begun to outstrip demand, creating downward pressure on the rents landlords can charge, Fitch noted during Wednesday's call. These landlords also face rising interest rates and insurance premiums, coupled with decreasing apartment values.

These factors have weighed on several regional banks with high exposure to the asset class, and in particular those most exposed to rent-controlled multifamily loans, where landlords face a ceiling on rent increases to offset rising costs.

"Especially in the more stringent rent-controlled areas, there is a limited ability to make up that difference," said Brian Thies, senior director at Fitch, on Wednesday's call.

"So I would say it can be a concern for loan performance at this point."

This was seen in late February, when regional bank New York Community Bancorp posted $2.7 billion in losses and a $552 million provision for credit losses in its fourth quarter, including on a New York-based rent-controlled multifamily loan.

Fitch highlighted 10 banks with the greatest multifamily loan exposure as of year-end 2023. Flagstar Bank , which merged with New York Community Bancorp in 2022, topped the list with 43.6% of its loan portfolio in multifamily.

Other banks with a high proportion of multifamily loans include First Foundation Bank, Dime Community Bank , Pacific Premier Bank and Apple Bank for Savings , according to Fitch.

These and other banks are exposed to rent-controlled multifamily loan markets in states with stringent rent-control laws including California, New York, New Jersey and Oregon.

There were 49 banks at the end of 2023 with at least 5% of multifamily loans past due on their payments, the ratings agency noted. Most of these consisted of regional and community banks.

The most capital-constrained banks will likely look to sell more of these loans - and at a loss, the Fitch analysts noted.

"We would consider most U.S. banks as well-reserved currently for multifamily lending," Thies said.

"But it's generally going to come down to the value of the collateral and how readily the bank can dispose of that."

(Reporting by Matt Tracy; editing by Costas Pitas)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Aldeyra Therapeutics Expands RASP Platform to Include Central Nervous System Diseases
Aldeyra Therapeutics Expands RASP Platform to Include Central Nervous System Diseases
Nov 13, 2025
07:41 AM EST, 11/13/2025 (MT Newswires) -- Aldeyra Therapeutics ( ALDX ) said Thursday it is expanding its RASP platform to include programs targeting central nervous system diseases associated with inflammation. The company said new preclinical results in models of Parkinson's disease and amyotrophic lateral sclerosis showed improved grip strength, balance, and biomarkers of central nervous system function. The results...
Arbutus Biopharma Q3 revenue and net loss miss analyst estimates
Arbutus Biopharma Q3 revenue and net loss miss analyst estimates
Nov 13, 2025
Overview * Arbutus Q3 revenue and net income missed analyst expectations * Company reports 46% of Phase 2a patients discontinued treatment in imdusiran trials * Arbutus continues litigation against Moderna and Pfizer/BioNTech over LNP technology Outlook * Favorable claim construction ruling in Pfizer-BioNTech litigation, Moderna trial set for March 2026 * 46% of Phase 2a patients discontinued treatment, showing potential...
Sagimet Biosciences Q3 net loss narrows as costs drop
Sagimet Biosciences Q3 net loss narrows as costs drop
Nov 13, 2025
Overview * Sagimet reports Q3 net loss of $12.9 mln * R&D expenses for Q3 2025 decreased to $9.7 mln from $12.7 mln in Q3 2024 * Cash and equivalents stand at $125.5 mln as of September 30, 2025 Outlook * Sagimet anticipates Phase 1 trial data readout for denifanstat and resmetirom in 1H 2026 * Company plans Phase 2...
Top Premarket Gainers
Top Premarket Gainers
Nov 13, 2025
07:41 AM EST, 11/13/2025 (MT Newswires) -- Mersana Therapeutics ( MRSN ) stock was up more than three-fold pre-bell Thursday after the company agreed to be acquired by Day One Biopharmaceuticals (DAWN) in a deal worth $285 million. Sealed Air ( SEE ) shares were 21% higher after The Wall Street Journal reported late Wednesday that the company is in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved